Table 4.
Ongoing clinical trials investigating immune checkpoint inhibitor - based clinical trials in the adjuvant and neoadjuvant setting
|
NCT
|
Phase
|
Study drugs
|
Treatment setting
|
Endpoint
|
Estimated End of Trial
|
| NCT03383458 | 3 | NIVOLUMAB vs PLACEBO | Adjuvant | RFS | June 2025 |
| NCT03867084 | 3 | PEMBROLIZUMAB vs PLACEBO | Adjuvant | RFS, OS | June 2025 |
| NCT03847428 | 3 | DURVALUMAB + BEVACIZUMAB vs PLACEBO | Adjuvant | RFS | September 2023 |
| NCT04102098 | 3 | ATEZOLIZUMAB + BEVACIZUMAB vs PLACEBO | Adjuvant | RFS | July 2027 |
| NCT03859128 | 2/3 | TORIPALIMAB vs PLACEBO | Adjuvant | RFS | April 2024 |
| NCT03839550 | 2 | CAMRELIZUMAB + APATINIB | Adjuvant | RFS | February 2023 |
| NCT04418401 | 2 | ANTI-PD1 + DONAFINIB | Adjuvant | RFS | June 2023 |
| NCT03510871 | 2 | NIVOLUMAB + IPILIMUMAB | Neoadjuvant | ORR, downstaging rate | December 2022 |
| NCT04123379 | 2 | NIVOLUMAB + CCR2/5-inhibitor vs NIVOLUMAB +ANTI-IL8 | Neoadjuvant | Safety | October 2024 |
| NCT03222076 | 2 | NIVOLUMAB | Neoadjuvant | Safety | September 2022 |
| NCT03682276 | 1/2 | NIVOLUMAB + IPILIMUMAB | Neoadjuvant | Safety, Delay to surgery | September 2022 |
| NCT03383458 | 1 | NIVOLUMAB vs PLACEBO | Adjuvant | RFS | June 2025 |
| NCT04425226 | N/A | PEMBROLIZUMAB + LENVATINIB | Neoadjuvant | RFS, ORR | December 2025 |
NCT: Number of the clinical trial (Clinicaltrials.gov); RFS: Recurrence-free survival; OS: Overall survival; RFS: Recurrence-free survival; ORR: Overall response rate.